The session’s core message is that better measurement of the human body can make cancer treatment more personal, safer, and more effective. The host opened by asking whether anyone in the audience felt they had “100% visibility and understanding” of their own body and noted that no one did, despite the presence of advanced technology and AI. This set up the introduction of two health-tech founders: Fanny of Alithea Bio, focused on reducing harmful side effects from immunotherapies, and Angela of TimeTeller, focused on measuring the body’s internal clock to identify optimal timing for eating, sleeping, sports, and cancer treatment. Han Dan, a TU Munich–educated mechanical engineer working at TDK Ventures in Munich, moderated the conversation.

Angela explained that TimeTeller emerged from frustration in clinical studies, where patients were stopping cancer treatment because of side effects. Her team was developing a technique to measure patients’ internal clocks and saw evidence that biological timing could make treatments less toxic and more effective. The decision point was whether to publish another paper or act beyond academia; after a family discussion, she used savings to fund the first patent, which became the origin of TimeTeller. Fanny described Alithea Bio’s founding around the belief that cancer can be curable and that immunotherapies, while powerful because they boost the immune system to attack tumor cells, can also damage healthy organs such as the heart or kidneys. Her goal is for patients to benefit from immunotherapies without side effects.

The discussion then turned to the challenge of translating deep science into healthcare products that actually reach patients. Angela said the hardest part for a scientist was moving from discoveries, publications, patents, and international recognition into a real-world product. TimeTeller addressed market access and reimbursement by working with Germany’s largest health insurer, Techniker Krankenkasse, which she said has more than twelve million insured people, and brought TimeTeller to cancer patients at the end of the previous year. Fanny emphasized a similar scaling challenge: Alithea Bio has built what she described as the world’s largest immuno-oncological platform, with more than twenty-three million identifications, and is already generating revenue from pharma and biotech drug developers, but the key next step is moving validation from R&D into the clinic and ultimately toward standard of care. She connected this need for speed and clinical scaling to raising a seed round.

Finally, the moderator asked where AI creates value when combined with highly specific biological data. Angela was explicit that TimeTeller’s business is based on biological data, not AI itself. The company uses saliva samples to determine the internal clock of patients, and AI supports the interpretation and application of that data. She claimed the approach can identify the best time for cancer patients to take therapy for fewer side effects and more efficacy, citing “five times less side effects” and “double survival.” Fanny began to explain Alithea Bio’s angle from lab-generated, proprietary, massive, unique data that can support prediction, but the provided transcript ends mid-answer at 8:31, before the full conclusion of that section is available.